FibroGen Inc. has announced the entry into a fourth amendment to its financing agreement with investment funds managed by Morgan Stanley Tactical Value. This amendment, dated August 12, 2025, further reduces the minimum qualified cash balance that FibroGen is required to maintain in its U.S. deposit or securities accounts from $18.75 million to $15 million. The agreement, originally dated April 29, 2023, and amended multiple times, involves Wilmington Trust National Association acting as the administrative agent for the lenders. The amendment aims to provide FibroGen with increased financial flexibility. Further details can be found in the full text of the Fourth Amendment, filed as Exhibit 10.1 to FibroGen's Current Report on Form 8-K.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.